Ironwood subsidiary settles Ferring IP litigation with $12.5M payment, license amendment

IRONWOOD PHARMACEUTICALS INC

VectivBio to pay Ferring $12.5M ($7.5M upfront, $5M by Dec 31, 2026) under amended license.
High single-digit royalty on net sales for 7 years after first commercial sale, then low single-digit royalty.
Amendment resolves Ferring's trade secret misappropriation lawsuit in E.D. Tex.
Ironwood guarantees VectivBio's $12.5M payment obligations under the amendment.
Clarified ownership of Contested Patents and Arising Intellectual Property exclusively to VectivBio.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

IRONWOOD PHARMACEUTICALS INC amended Third Amendment to Amended and Restated Exclusive License Agreement with Ferring International Center S.A. valued at $12.5 million aggregate payment to Ferring, including an initial payment of $7.5 million and a secon (effective 2025-12-18).

Action: amendment
Agreement: license
Counterparty: Ferring International Center S.A.
Value: $12.5 million aggregate payment to Ferring, including an initial payment of $7.5 million and a secon
Effective: 2025-12-18

Exact text from the filing

On December 18, 2025, Ironwood Pharmaceuticals, Inc. (the "Company"), solely for purposes of a limited payment guarantee, VectivBio AG, a wholly owned subsidiary of the Company ("VectivBio"), and Ferring International Center S.A. ("Ferring"), entered into that certain third amendment (the "Amendment") to the amended and restated exclusive license agreement, dated as of December 6, 2016, as amended, by and between GlyPharma Therapeutic Inc. (as predecessor to VectivBio) and Ferring (the "Ferring License Agreement").

View on SEC.gov

Browse all material agreements →

IRONWOOD PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001104659-25-123974

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.